

EXHIBIT S24 TO DECLARATION OF  
STEPHEN G. SCHWARZ IN SUPPORT OF  
PLAINTIFFS' MOTION FOR CLASS  
CERTIFICATION

PHONE CONVERSATION REPORT  
EUGENE BERMAN  
DUPONT  
(302) 774-9503

TO: R. J. DAVIS  
L. J. MAGILL  
T. J. SCHEUERMAN  
FROM: L. C. KROGH

AUG 6 1979

To: ~~L. C. KROGH - 65E~~  
J. D. LAZERTE - 236-1  
From: R. A. PROKOP  
Subject: PHONE CONVERSATION REPORT  
Date: JULY 26, 1979 - Incoming Call 1:45 P.M.

I gather we should get the fluorochemical exposure committee together for a meeting to determine our course of action in view of this phone report. Would you agree that we should do this soon?

LCK:jmb  
7/30/79

cc: L. D. DeSimone  
J. D. LaZerte  
R. A. Prokop  
F. D. Griffith  
F. A. Ubel

**3M**

Subject: Disclosure of Information on Levels of Fluorochemicals in Blood.

COMMENTS:

Eugene is an attorney for DuPont who has responsibility for TSCA. He heads a committee who is responsible for deciding how to handle issues which involve the safety of employees or products. The committee consists of the Corporate Director of Safety, a representative from Haskell Laboratory (McKusick), and representatives from Employee Relations and other operating departments.

The committee reviewed the information on fluorochemicals in blood and came to the same conclusions as 3M--that since there were no adverse health effects, there was no reason for an 8E notification under TSCA.

Eugene referred to our meeting with DuPont personnel in Chicago on July 20, 1979. The presentation by F. Ubel on the serum organic fluorine levels of the individual who was removed from exposure to fluorochemicals generated a great deal of interest, but also some concern. Eugene focused on the reason for removing this employee from exposure. The DuPont committee felt that someone in the future (with hindsight) might question why this employee was removed from exposure even though we could find no adverse health effects, i.e., why was he removed from exposure when his level reached 70 rather than 100 ppm. The DuPont committee saw this as a potential problem.

DuPont has three action levels on problems such as this. The first level is a notification such as an 8E notification to the appropriate government agency. In such a case the notification would be such that it would be known at top levels in the agency. At the second level, the information might be passed to someone within the agency who they know and have a good relationship with. The information in this category would not be as serious as that which would be handled at the first level. The third action level is publication, and may take the form of a journal article or letter to the editor of a journal such as "Science". This is the level that the DuPont committee feels applies to our own situation and to theirs.

Exhibit  
2723

State of Minnesota v. 3M Co.,  
Court File No. 27-CV-10-28862

Phone Conversation Report  
Eugene Berman - DuPont  
July 26, 1979 - 1:45 P.M.

Page 2

Eugene asked about our plans to publish information on fluorochemicals in blood. I told him we had published an article on analytical methodology and will publish another in the near future. I also told him that we were considering publishing some of the subacute animal studies. He was more interested in our plans to publish serum organic fluorine levels which we found in our employees.

The DuPont committee feels that these levels should be published. In the absence of knowledge of serum organic fluorine levels of 3M employees, DuPont would probably publish the serum organic fluorine levels of their own employees in some manner. Eugene emphasized that the committee is recommending that 3M publish. They are not saying that DuPont will publish if 3M does not.

I told Eugene that I thought we would be reluctant to publish any serum organic fluorine levels at the present time since we do not know what they mean. I also told him that I thought the earliest that we might be willing to publish would be after completion of our epidemiology study. He agreed that the values, at present, have no meaning and that more information should be obtained.

Eugene would like an answer for the DuPont committee as to whether or not we will publish the serum organic fluorine levels of our employees, but is not in a hurry. I told him I would inform L.C. Krogh of our conversation and get an answer for the DuPont committee.



RAP:df